Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
CATIE Comes to Surprising Conclusions

16 October 2005. Should some of the older, and cheaper, antipsychotic drugs be pulled out of semi-retirement in the United States and given a chance to compete with the atypical (second-generation) drugs? With the report of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) in the New England Journal of Medicine on September 19, this is a question that psychiatrists and patients must grapple with, not to mention those who hold the purse strings for public and private health payers.

The CATIE study, led by Jeff Lieberman of Columbia University and a host of colleagues at other institutions, found no significant differences in effectiveness (as measured by time to discontinuation) of the older generation drug perphenazine versus the second-generation drugs quetiapine, risperidone, or ziprasidone. The atypical drug olanzapine did show modest advantages over the other drugs in the study, a fact tempered by olanzapine's metabolic side effects.

Notably missing was the "original" atypical antipsychotic drug, clozapine. Clozapine was excluded from the study because the authors felt it had demonstrated its superiority over the other drugs in terms of efficacy, but also because it can severely deplete white blood cells, and its use has diminished with the development of other atypical drugs. Indeed, as Robert Freedman of the University of Colorado notes in an accompanying editorial, the atypical drugs in this study represent attempts to emulate clozapine's success—believed to stem from lower affinity than earlier drugs for the dopamine D2 receptor and greater affinity for serotonergic and noradrenergic receptors—without clozaril's danger to the immune system. While they have been successful in this regard, the newer atypical antipsychotics brought along other, albeit milder, side effects, such as disruptions of metabolic function (for a review, see Newcomer, 2004). Freedman also notes that the newer atypicals were approved on the basis of efficacy results equivalent to those of the older drugs, not that of clozapine.

Despite a relative lack of data on the real-world effectiveness of the atypical antipsychotics, they account for some 90 percent of antipsychotic sales in the United States, and about 50 percent in Europe. That's a big slice of a market estimated at more than $10 billion annually.

Real-world Assessments of Effectiveness
Funded by the National Institute of Mental Health, the CATIE study gathered data from 2001 through 2005, recruiting nearly 1,500 patients at 57 diverse U.S. sites, ranging from university clinics and Veterans Affairs centers to private practices. The patients were randomized to receive one of the aforementioned drugs for 18 months in a double-blind format.

The primary endpoint of the CATIE study was time to discontinuation of the drug, a quite different endpoint from the efficacy studies conducted to win drug approval, which report on reductions in positive or negative symptoms during a short trial of several months. But the length of time a patient sticks with a drug is an endpoint that makes a lot of sense in a disorder where all the drugs have notable side effects and patients routinely stop taking the drugs, either as a consequence of their illness or because of side effects.

And by this measure, the study reinforces what patients and psychiatrists know from experience—the drugs are not well tolerated. Seventy-four percent of patients stopped taking the drug to which they had initially been randomized. This included 64 percent of those randomized to olanzapine, 74 percent taking risperidone, 75 percent taking perphenazine, 79 percent taking ziprasidone, and 82 percent taking quetiapine. That perphenazine fell in the middle of the pack is a big surprise.

Supporting an earlier meta-analysis (Davis et al., 2003), olanzapine proved more successful than the other candidates in the study, with a somewhat longer time to discontinuation. However, olanzapine brought on greater metabolic side effects, such as elevated blood glucose, cholesterol, and weight gain.

Searching for New Directions
There is no doubt that new treatments are needed. Among the current possibilities, Freedman has been working on the α-7 nicotinic acetylcholine receptor as an alternative target for treatment (for a review, see Martin et al., 2004). There is hope that work in glutamatergic systems could produce drug candidates (for a review, see Coyle and Tsai, 2004), and tweaking the current drugs may also pay off, at least in terms of reducing side effects. For example, partial agonism can achieve results similar to receptor antagonism, a strategy successfully pursued in hypertension treatment. The partial dopamine D2 agonist aripiprazole may prove to have fewer side effects than do the current crop of drugs, hopefully with equivalent or better efficacy (for a review, see Ohlsen and Pilowsky, 2005).

And as Robin Murray mentions in his interview with SRF, there is evidence that cognitive or behavioral modification therapy can make a substantial difference with some symptoms of schizophrenia. However, such therapy is expensive, requiring a sophisticated, ergo expensive, healthcare system able to maintain contact with mentally ill patients over the long term.

Are there other places we can look to for hope within the current understanding of schizophrenia pathophysiology? We invite you to leap into the Schizophrenia Research Forum community with commentary on the significance of this study, any methodological objections, or on the directions you think are most promising for further therapeutic advances.—Hakon Heimer.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Abstract

Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1286-8. Epub 2005 Sep 19. Abstract

Comments on News and Primary Papers
Comment by:  Daniel Weinberger, SRF Advisor
Submitted 18 October 2005 Posted 18 October 2005

The Lieberman et al. CATIE study is a landmark large-scale...  Read more

View all comments by Daniel Weinberger

Comment by:  Scott Hemby
Submitted 19 October 2005 Posted 19 October 2005
  I recommend the Primary Papers

Comment by:  David Lewis, SRF Advisor
Submitted 19 October 2005 Posted 19 October 2005
  I recommend the Primary Papers

Comment by:  Max Schubert
Submitted 19 October 2005 Posted 19 October 2005
  I recommend the Primary Papers

I also have not seen the response at that dose of...  Read more

View all comments by Max Schubert

Comment by:  Iulian Iancu
Submitted 20 October 2005 Posted 20 October 2005
  I recommend the Primary Papers

It seems that the doses used are not equivalent, and the...  Read more

View all comments by Iulian Iancu

Comment by:  Xiang Zhang
Submitted 20 October 2005 Posted 21 October 2005
  I recommend the Primary Papers

There is evidence that the Chinese traditional medicines...  Read more

View all comments by Xiang Zhang

Comment by:  Alonso Montoya
Submitted 21 October 2005 Posted 21 October 2005
  I recommend the Primary Papers

Comment by:  Alexander Miller
Submitted 21 October 2005 Posted 21 October 2005
  I recommend the Primary Papers

Comment by:  Marvin Swartz
Submitted 26 October 2005 Posted 26 October 2005

Reply to Dr. Weinberger's questions about the...  Read more

View all comments by Marvin Swartz

Comment by:  William Carpenter, SRF Advisor (Disclosure)
Submitted 26 October 2005 Posted 26 October 2005

The antipsychotic drugs mainly treat psychosis (in...  Read more

View all comments by William Carpenter

Comment by:  Daniel Weinberger, SRF Advisor
Submitted 29 October 2005 Posted 30 October 2005

Dr. Swarz's comment providing data from the SCAP study is...  Read more

View all comments by Daniel Weinberger

Comment by:  Robert McClure (Disclosure)
Submitted 31 October 2005 Posted 1 November 2005
  I recommend the Primary Papers

It would be interesting to learn from Dr. Swartz and the...  Read more

View all comments by Robert McClure

Comment by:  Captain Johann Samuhanand
Submitted 7 November 2005 Posted 7 November 2005

Is there any published evidence that gingko biloba could...  Read more

View all comments by Captain Johann Samuhanand

Comment by:  Xiang Zhang
Submitted 8 November 2005 Posted 9 November 2005
  I recommend the Primary Papers

Reply to comment by Johann Samuhanand
To our...  Read more

View all comments by Xiang Zhang

Comment by:  Patricia Estani
Submitted 25 November 2005 Posted 25 November 2005
  I recommend the Primary Papers

I recommend this clear and well-written paper for students...  Read more

View all comments by Patricia Estani

Comment by:  Mike Irwin
Submitted 29 November 2005 Posted 29 November 2005
  I recommend the Primary Papers

Comment by:  Patricia Estani
Submitted 13 December 2005 Posted 13 December 2005
  I recommend the Primary Papers

The most important current development of new...  Read more

View all comments by Patricia Estani

Comment by:  Robert Fisher
Submitted 24 December 2005 Posted 28 December 2005
  I recommend the Primary Papers

[Disclosure: R. Fisher was Study Coordinator, Recruiter,...  Read more

View all comments by Robert Fisher
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright